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Abstract
Background: Visceral leishmaniasis is the most severe form of leishmaniasis and no effective vaccine exists. The
use of live attenuated vaccines is emerging as a promising vaccination strategy.
Results: In this study, we tested the ability of a Leishmania infantum deletion mutant, lacking both HSP70-II alleles
(ΔHSP70-II), to provide protection against Leishmania infection in the L. major-BALB/c infection model.
Administration of the mutant line by either intraperitoneal, intravenous or subcutaneous route invariably leads to
the production of high levels of NO and the development in mice of type 1 immune responses, as determined by
analysis of anti-Leishmania IgG subclasses. In addition, we have shown that ΔHSP70-II would be a safe live vaccine
as immunodeficient SCID mice, and hamsters (Mesocricetus auratus), infected with mutant parasites did not
develop any sign of pathology.
Conclusions: The results suggest that the ΔHSP70-II mutant is a promising and safe vaccine, but further studies in
more appropriate animal models (hamsters and dogs) are needed to appraise whether this attenuate mutant
would be useful as vaccine against visceral leishmaniasis.
Background
Leishmaniasis is a vector-borne disease that is caused
by the infection of protozoan parasites of the genus Leish-
mania. The extracellular promastigote forms of Leishma-
nia are inoculated into humans (and other mammalian
hosts) by sandflies (phlebotomine insects), after which the
parasites undergo phagocytosis by macrophages and trans-
form to intracellular amastigotes. Clinical manifestations
of leishmaniasis are particularly diverse [1], ranging from
subclinical (unapparent infections) to visceral leishmania-
sis (VL), which is usually fatal when untreated. Other com-
mon forms of the disease are mucocutaneous (MCL),
diffuse cutaneous (DCL) and cutaneous leishmaniasis
(CL). The clinical outcomes depends upon a number of
factors, including the species (and strain) of the parasite,
as well as the host’s genetically determined immune
responses. Thus, Leishmania major and many other Leish-
mania species cause CL, Leishmania donovani and Leish-
mania infantum are mainly associated with VL, whereas
MCL results after infection with parasites from the Leish-
mania braziliensis complex [2].
Leishmaniasis threatens 350 million people worldwide,
mainly in developing countries. Annual incidence is esti-
mated at 2 million cases and the overall prevalence is 12
million people [3]. In developing and under-developed
parts of the world, AIDS and other immunosuppressive
syndromes add to the higher risk of leishmaniasis [4]. In
spite of its incidence, leishmaniasis is a neglected disease.
Current control strategies rely on reservoir and vector
control and pharmacological drugs, but new treatment
strategies are clearly needed [5]. Abundant clinical and
experimental evidence indicates that leishmaniasis would
be preventable by vaccination, but anti-leishmanial vac-
cines for human use have yet to be developed [6-10].
Effective vaccination against human CL has been prac-
ticed for centuries by deliberate inoculation of living
organisms from the exudates of active lesions or, more
recently, by the inoculation of cultured Leishmania pro-
mastigotes (process known as “leishmanization”) [11].
The appearance of complications, i.e. developing of
severe disease in some individuals, led to abandoning the
* Correspondence: jmrequena@cbm.uam.es
Centro de Biología Molecular “Severo Ochoa” (CSIC-UAM), Universidad
Autónoma de Madrid, Madrid, Spain
Carrión et al. Parasites & Vectors 2011, 4:150
http://www.parasitesandvectors.com/content/4/1/150
© 2011 Carrión et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
use of live Leishmania as a prophylactic vaccine. Never-
theless, leishmanization is still currently practiced in
some countries including Uzbekistan, Afghanistan, Iraq,
and Iran [12], and there are recent efforts to standardize
it as a live vaccine and also to use it for rapidly assessing
the efficacy of new vaccines [13]. On the other hand, first
generation vaccines (or killed vaccines), prepared using
inactivated whole parasites, have been the subject of
many studies over decades and are the only vaccine can-
didates for leishmaniasis which have undergone phase 3
clinical trials. However, evidence of protective efficacy
has not emerged from those clinical trials [14].
The ineffectiveness of vaccines based on either killed
parasites or recombinant proteins seems to be a conse-
quence of the short-term immunity they induce [15]. On
the other hand, several studies in mice indicate that persis-
tent parasites are important to maintain durable, anti-
Leishmania memory responses [12,16]. These findings
have led to the exploration of the use of live, genetically
modified-parasites as an appealing strategy for developing
vaccines against leishmaniasis [17,18]. Defined genetic
alterations of the Leishmania genome can be achieved
through homologous recombination [19], allowing disrup-
tion of essential genes for virulence and/or host survival.
The first Leishmania mutant generated by gene replace-
ment assayed as a potential Leishmania vaccine was an
L. major line lacking the gene coding for dihydrofolate
reductase-thymidylate synthase (DHFR-TS) [20]. This thy-
midine-auxotroph mutant was found to persist in BALB/c
mice for up to 2 months, but it was incapable of causing
disease. Interestingly, this dhfr-ts knockout was able to eli-
cit substantial resistance in mice to a subsequent challenge
with virulent L. major. However, immunizations with dhfr-
ts knockouts derived from L. chagasi, L. donovani, or
L. major did not protect against L. chagasi infection in
BALB/c mice [21]. In another report, disruption of BT1
genes, encoding a biopterin transporter, in Leishmania
donovani allowed the generation of a mutant line with
reduced capacity for inducing infection in mice [22].
Furthermore, it was found that inoculation of BT1 null
parasites elicits protective immunity in mice against an
L. donovani challenge. Another mutant assayed as attenu-
ated vaccine has been an L. major LPG2-knockout, which
cannot synthesize LPG and other phosphoglycans; despite
this defect, upon infection of mice, the mutants persist for
several months without causing disease [23]. When BALB/
c mice infected with lpg2- parasites were challenged with
virulent L. major, they were protected from disease [24].
However, the in vivo follow-up of these mutants led to the
identification of a compensatory mutant (lpg2-REV) that
regained virulence even in the absence of phosphoglycan
synthesis [25]. In addition, it was found that L. mexicana
lpg2- mutants retained their virulence for macrophages
and mice [26]. Another genetically-modified L. mexicana
line, lacking cysteine proteinase genes cpa and cpb, was
successfully used to protect against homologous infection
in mice and hamsters [27,28]. Likewise, vaccination of
BALB/c mice with an L. mexicana null mutant for GDP-
mannose pyrophosphorylase (GDP-MP) conferred signifi-
cant and long lasting protection against infection with
virulent parasites [29]. Recently, it has been shown that
BALB/c mouse infection with L. infantum mutant lacking
one of the two SIR2 (silent information regulatory 2)
alleles induced a high degree of protection against a
virulent challenge [30]. More recently, it was reported
that immunization with a centrin deletion mutant of
L. donovani protected mice against infection with either
L. donovani or L. braziliensis [31].
In this study, we analyzed the inmunoprotective ability
of an L. infantum deletion mutant, lacking HSP70 type
II gene (ΔHSP70-II), as a live vaccine against leishma-
niasis in the L. major-BALB/c infection model. Immuni-
zation with this mutant line elicited specific immune
responses and significant levels of protection against a
challenge with virulent L. major promastigotes.
Methods
Animals and parasites
Experiments were performed in accordance with proce-
dures approved by the Spanish Research Council
Bioethics Committee. For animal experimentation, we
followed the ethical principles dictated by the European
Commission (Directive 86/609/CEE) for use of labora-
tory animals.
Female BALB/c and BALB SCID (CB-17scid) mice (6-8
week old), and male hamsters (Mesocricetus auratus; 8
week old) were purchased from Harlan Interfauna Iber-
ica S.A. (Barcelona, Spain) and maintained in specific-
pathogen-free facilities.
The ΔHSP70-II null mutant (Δhsp70-II::NEO/Δhsp70-
II::HYG) is a cloned line that was generated by targeted
deletion of both HSP70-II alleles in the L. infantum
strain MCAN/ES/96/BCN150 [32]. L. major promasti-
gotes (strain MHOM/IL/80/Friedlin; clon V1) were also
used in this study. Promastigotes of both species were
grown in RPMI 1640 culture medium supplemented
with 10% heat-inactivated FBS, 100 U/ml penicillin and
100 μg/ml streptomycin.
Infections
The virulence of L. infantum and L. major parasites was
maintained by passage in hamsters and BALB/c mice,
respectively. For infections, amastigote-derived promasti-
gotes with less than 3 passages in vitro were used. For
infection of mice with the ΔHSP70-II mutant (107 pro-
mastigotes/mouse), three routes were assayed: intravenous
(IV; tail-vein injection), intraperitoneal (IP), and
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subcutaneous (SC; right hind-footpad). Mice from the
control groups were inoculated with 0.1 ml of PBS.
Hamsters were infected with 5 × 107 ΔHSP70-II pro-
mastigotes by the intracardiac route (IC) as described
elsewhere [33]. Age- and sex-matched hamsters were
maintained uninfected and used as control for immuno-
logical determinations.
L. major metacyclic promastigotes were purified from
stationary phase cultures. Briefly, promastigotes were
resuspended in phosphate buffer saline (PBS) at 108 cells/
ml, and peanut agglutinin (Vector laboratories) was added
at 50 μg/ml; the sample was incubated for 25 min at room
temperature. After centrifugation at 900 × g for 10 min,
the supernatant contained the non-agglutinated metacyclic
promastigotes. A thousand of metacyclic promastigotes in
50 μl were injected in the right hind-footpad of BALB/c
mice. The growth of the lesion was monitored at indicated
time points by measuring the thickness of the footpad
using a dial caliper. The contralateral footpad of each ani-
mal represented the control value and the swelling calcu-
lated as: thickness of the right footpad - thickness of the
left footpad.
Determination of the tissue parasite burden was carried
out by quantitative limiting-dilution as described by Buffet
and co-workers [34]. Briefly, whole lymph nodes, spleens
and weighed pieces of liver were individually homogenized
in Schneider’s medium supplemented with 20% inacti-
vated-FBS, 100 U/ml penicillin and 100 μg/ml streptomy-
cin. The homogenates, in quadruplicate, were serially
diluted across 96-well plates. Wells were examined for the
presence of motile parasites after 2 (for L. major) or 4 (for
L. infantum) weeks of culturing at 26°C. The number of
parasites per organ was calculated as follows: parasite
burden = (geometric mean of titer from quadruplicate cul-
tures) × (reciprocal fraction of the homogenized organ
inoculated into the first well). The titer was the reciprocal
of the last dilution in which parasites were observed.
Analysis of antibody responses
A Leishmania crude antigen was prepared from
L. infantum promastigotes by incubation of microorgan-
isms in lysis buffer (1% Triton X-100, 150 mM NaCl,
10 mM Tris-HCl pH 8 and 1 mM PMSF) for 15 min.
Afterwards, the suspension, kept on ice, was sonicated
until a decrease in viscosity was observed. The insoluble
material was pelleted at 10 000 × g for 5 min and the
supernatant was immediately stored at -70°C until use.
Sera were taken from all groups of mice before and 4
weeks after inoculation of the ΔHSP70-II promastigotes.
Serum samples were analyzed for specific antibodies
against Leishmania total antigen by standard ELISA
assay. Briefly, standard plates (NUNC A/S, Roskilde,
Denmark) were coated overnight at 4°C with 100 μl of
Leishmania crude antigen (2 μg/ml in PBS). The sera
from mice were assayed using two-fold serial dilutions.
As secondary antibodies the following peroxidase-conju-
gates (Nordic Immunology Laboratories, Tilburg, The
Netherlands) were used: goat anti-mouse IgG1 (1:1000
dilution) and goat anti-mouse IgG2a (1:1000 dilution).
Orthophenylenediamine dihydrochloride (DAKO A/S,
Glostrup, Denmark) was used as a peroxidase substrate.
After 30 min, the reaction was stopped by the addition
of 100 μl of 1 M H2SO4, and the absorbance was read
at 450 nm. Titer was calculated as the reciprocal of the
serum dilution that gave an absorbance above the mean
value of preimmune sera plus three standard deviations.
Antibody responses in hamsters were determined by
ELISA using the same antigen and coating conditions
indicated above. The primary sera were assayed at 1:200
dilution, and the secondary antibody (RAHa/IgG(H+L)/
PO conjugate; Nordic) was used at 1:1500 dilution.
Nitric oxide (NO) determinations
Peritoneal macrophages from the different groups of
mice (either control or infected with the ΔHSP70-II
mutant by different routes, see above) were cultured at
a concentration of 106 cells per milliliter in RPMI 1640
culture medium supplemented with 10% heat-inacti-
vated FBS, 100 U/ml penicillin and 100 μg/ml strepto-
mycin. Soluble Leishmania antigen (SLA; see below) was
added to a final concentration of 50 μg/ml. After 48 h of
incubation at 37°C, cell-free supernatants were collected
and the nitrite level was stimulated using the Griess
reaction kit (Sigma-Aldrich) according to the manufac-
turer’s protocol. The basal NO production by murine
macrophages was determined after culturing of the cells
in the absence of SLA.
Lymphoproliferation assays
At nine months after infection with ΔHSP70-II promas-
tigotes, hamsters (n = 4) were euthanized and single cell
suspensions from the spleens were made. Splenocytes
from age- and sex-matched hamsters were used as con-
trols. Cells (2.5 ×106/ml) were plated in 96-well plates
(200 μl) in RPMI medium supplemented with 10% heat-
inactivated FBS, 100 U/ml penicillin and 100 μg/ml
streptomycin. Cells were stimulated with either Conca-
navalin A (ConA; 1 μg/ml) or SLA (10 μg/ml) for 72 h.
As control, unstimulated cultures were maintained in
parallel. Proliferation was evaluated after addition of
1 μCi of [3H]thymidine (5 Ci/mmol) for the last 16-h of
incubation. Incorporation of thymidine was assessed by
scintillation counting.
SLA was prepared by three freezing and thawing
cycles of stationary promastigotes of L. infantum sus-
pended in PBS. After cell lysis, soluble antigens were
separated from the insoluble fraction by centrifugation
for 15 min at 12,000 ×g.
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Results and discussion
Inoculation of ΔHSP70-II parasites protects BALB/c mice
against L. major challenge
In a previous work [35], we found that L. infantum
parasites lacking the HSP70-II gene (ΔHSP70-II) have a
virulence greatly reduced. Thus, after infection of
BALB/c mice with 10 millions of ΔHSP70-II promasti-
gotes, the parasite loads in liver and spleen were more
than 1000-fold lower than those achieved after infection
with wildtype (WT) parasites. Nevertheless, the immune
response elicited in mice by the infection with ΔHSP70-
II parasites showed immunoprotective features. Thus,
even though mice infected with ΔHSP70-II promasti-
gotes had low levels of Leishmania-specific antibodies,
the IgG2a/IgG1 ratio was higher in ΔHSP70-II infected
mice than in mice infected with the WT promastigotes
[35]. IgG2a dominance in the immune response is asso-
ciated with protective responses against Leishmania
infection [36].
To investigate whether ΔHSP70-II parasites would
provide protection to leishmaniasis, we used the
L. major-BALB/c infection model. In many ways, the
infection of BALB/c mice with L. major may be a bet-
ter model for human VL than for CL [37,38]. These
mice develop high antibody titers, and the parasites
frequently metastasize to distant locations including
the bone marrow, liver, and spleen. Similar to human
VL, BALB/c mice typically succumb to infection with
L. major [39]. Nevertheless, it should be clearly stated
that the hamster and the dog are better animal models
than the mouse for human VL [40]. For the experi-
ment, mice were intravenously infected with 107
ΔHSP70-II promastigotes, and 4 weeks later were chal-
lenged in the footpad with 1000 L. major metacyclics.
Control mice developed large, nonhealing cutaneous
lesions and had to be euthanized after 7 weeks. In con-
trast, mice previously infected with ΔHSP70-II para-
sites displayed a resistance phenotype: a reduced
inflammation was observed in one mouse, and no
lesions appeared in the rest of mice (Figure 1A). Mice
were sacrificed and the parasite burden determined in
the draining popliteal lymph node and spleen by limit-
ing dilution (Figure 1B). In agreement with lesion pro-
gression, mice previously infected with ΔHSP70-II
parasites had fewer parasites than controls; the differ-
ences were particularly dramatic when comparing the
parasite loads in the spleen. Dissemination of L. major
parasites to internal organs correlates with susceptibil-
ity in the mouse infection model [38]. Thus, inocula-
tion of L. major promastigotes into the dermis or the
footpad of BALB/c mice leads to the dissemination of
the parasite, after a short period (10-24 hours), to the
spleen, the liver, the bone marrow, and, occasionally,
the kidney. However, in similarly infected mouse
strains with a curative phenotype like C57BL/6, CBA/J,
and C3H/HeJ, the parasites remain localized in the
footpad and in the draining popliteal lymph node for
many days without evidence of dissemination. In con-
clusion, the results indicated that an effective protec-
tion was attained in BALB/c mice infected with the
ΔHSP70-II mutant.
Immunological and parasitological parameters associated
with the inoculation route
The above experiments demonstrate that IV inoculation
with ΔHSP70-II parasites confers a significant protection
against L. major infection in mice. In a new set of
experiments, we compared the immunological responses
observed after inoculation of the mutant by three inocu-
lation routes: intraperitoneal (IP), IV and subcutaneous
(SC). We first focused on the humoral immune response
and determined the titers of IgG1 and IgG2a antibodies
against Leishmania proteins by ELISA before and 4
weeks after inoculation of the mutant line in all three
groups. As shown in Figure 2A, the IgG2a titers were
higher than IgG1 titers for all groups, suggesting that
infection with ΔHSP70-II parasites, independent of the
inoculation route, leads to a predominant production of
anti-Leishmania antibodies of the IgG2a isotype.
Although inoculation through the IV route leads to con-
siderably higher titers (2-4 fold) of IgG2a antibodies in
comparison to the other inoculation routes (Figure 2A),
the highest IgG2a/IgG1 was observed in mice infected
through the SC route. IgG2a antibody formation is
dependent on IFN-g as an IgM-to-IgG2a switch factor
and is considered to be typical for a T helper type 1
(Th1) response; in contrast, IgG1 production depends
on IL-4 secreted by Th2 cells [41].
Because the production of NO by macrophages is a
key factor in killing Leishmania, we determined also the
level of NO produced by peritoneal macrophages from
ΔHSP70-II infected mice after in vitro re-stimulation
with SLA. Interestingly, significant levels of nitrites were
observed in the culture supernatants of macrophages of
the three infection-groups when compared with control
macrophages (Figure 2B). Nevertheless, production of
NO was clearly higher by SLA-stimulated macrophages
from mice infected with ΔHSP70-II parasites through
the IP route.
Finally, we analyzed the parasite burden in spleen and
liver of the different groups of ΔHSP70-II infected mice
(Figure 2C). No parasites were detected in BALB/c mice
four weeks after infection through the SC route suggest-
ing that the ΔHSP70-II mutant was unable to viscera-
lize. On the other hand, the parasite burden was higher
when the mutant is inoculated through the IV route
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Figure 1 Course of L.major infection in BALB/c mice vaccinated with ΔHSP70-II promastigotes. BALB/c mice (n = 5) were inoculated with
1 × 107 ΔHSP70-II promastigotes and, 4 weeks later, challenged with 1,000 metacyclic promastigotes of L. major. The control group
(unvaccinated) was challenged with an identical inoculum of L. major. (A) Course of lesion progression. (B) Parasite burdens in spleen and
popliteal lymph node (right foot). The data presented are representative of two experiments with similar results.
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Figure 2 Immunological and parasitological parameters associated with the inoculation route of ΔHSP70-II promastigotes in BALB/c
mice. Groups of mice (n = 4) were inoculated with 1 × 107 ΔHSP70-II promastigotes by the intraperitoneal (IP), intravenous (IV) or subcutaneous
(SC) route. (A) Four weeks after infection the anti-Leishmania specific IgG1 and IgG2a titers were determined by ELISA. Differences between IgG1
and IgG2a titers for each group of mice were compared by using the two-tailed paired Student’s t-test: *, p = 0.016; **, p = 0.066; ***, p = 0.019.
(B) Production of NO by peritoneal macrophages from ΔHSP70-II infected (IP, IV, and SC) or control mice. (C) Parasite burdens in spleen and liver
of ΔHSP70-II infected mice. The data are represented as the mean + standard deviation.
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than when the mutant is inoculated into the peritoneal
cavity.
ΔHSP70-II parasites are highly attenuated in susceptible
L. infantum animal models
Before considering the ΔHSP70-II mutant line as a can-
didate vaccine, it is critical that the parasites remains
attenuated, and that a selection of escape variants, in
which the infectivity is restored, does not occur as a
consequence of continuous passage in BALB/c mice.
Spontaneous recovery of virulence has been observed
for some attenuated Leishmania mutants, e.g. lpg2- [25],
LmxPK4- [42], and hsp100- [43].
The ΔHSP70-II mutant line was created in 2005 [32];
since then, the parasite has been used many times to
infect BALB/c, and recovery of virulence has not been
observed (see also Figures 2 and 3). To further explore
whether the ΔHSP70-II parasites would remain attenu-
ated in the absence of a functional immune system,
SCID mice lacking functional T and B cells were
infected. As shown in Figure 3, SCID mice infected with
ΔHSP70-II promastigotes showed even lower parasite
burdens than ΔHSP70-II-infected BALB/c mice (this is
especially true for the liver). At first glance this result
may be considered unexpected; however, after carefully
revising previous studies on Leishmania infection of
SCID mice, our findings may be expected. Certainly, the
parasite burdens in SCID mice are higher than those
observed in immunocompetent mice, but it is true at
long-term. However, if the parasite burdens are deter-
mined at short-term, the parasitemia is lower in the
SCID mice than in the BALB/c [30,44]. The reason may
be in the fact that SCID mice, perhaps as a compensa-
tory mechanism due to the lack of functional T and B
cells, have a relatively higher potential of functional NK
cells (see Solbach and Laskay [39] for further details).
As the ΔHSP70-II line has an intrinsic low capacity of
multiplication in mammalian hosts, the higher activity
or levels of NK cells in SCID may explain why the para-
site loads are lower in SCID mice than in BALB/c mice.
On the other hand, in the initial experiments of
BALB/c infection with this mutant line, no parasites
were recovered in the liver [35]; thus, it is likely that the
ΔHSP70-II parasite has evolved a liver tropism after in
vivo passing. Nevertheless, it should always be kept in
mind that the parasite burdens in ΔHSP70-II infected
BALB/c mice were three to four orders of magnitude
lower than those found in mice infected with the
L. infantum parental strain (BCN150); as reported pre-
viously [35], at 4 weeks post-infection, the total burdens
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Figure 3 Infectivity of ΔHSP70-II promastigotes in immunocompromised SCID mice. Groups (n = 4) of SCID mice were inoculated with 1
× 107 ΔHSP70-II promastigotes and the parasite burdens were determined in spleen and liver after 1 or 2 months post-infection. As control, a
group (n = 4) of BALB/c was similarly infected, and the parasite burdens were determined 1 month post-infection.
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per organ, in BCN150-infected BALB/c mice, were
around 2 million (6.3 logarithmic units) in spleen, and
80 million (7.9 logarithmic units) in liver. Even more
interestingly, we found that parasite burdens in
ΔHSP70-II-infected SCID declined at two months post-
infection and parasites were not detected in the liver at
this time (Figure 3). This finding demonstrates that
ΔHSP70-II parasites cannot replicate efficiently even in
immunocompromised SCID mice, which otherwise
when infected with L. infantum WT parasites develop a
progressive parasitemia [30]. Together, those results
confirm that ΔHSP70-II parasites would constitute a
safe vaccine.
Inbred strains of mice are not adequate models for
infectivity analysis of viscerotropic strains of Leishmania,
as mice naturally develop protective immunity against the
infection that leads to a clearance of the parasite [45].
Thus, we further assessed the virulence of the ΔHSP70-II
mutant in the golden hamster (M. auratus) model, which
is a laboratory animal that accurately reproduce pathologi-
cal aspects of human VL, such as an uncontrolled parasite
replication in the liver and spleen [33,46]. Furthermore,
golden hamsters are so susceptible for L. infantum infec-
tion that infective doses as low as 1000 parasites result in
fatal disease [33].
A group of four hamsters were intracardially inoculated
with 50 million ΔHSP70-II promastigotes and the ani-
mals were examined weekly for clinical symptoms of dis-
ease progression. Additionally, at two-month intervals,
blood samples were obtained and the humoral response
against Leishmania was assayed. Although weak, a speci-
fic anti-SLA antibody response was detected at two
months post-infection in all animals (data not shown).
Afterwards, the IgG reactivity decreased slightly, but a
specific response still remained detectable at 9 months
post-infection (Table 1). Apart from this, no other signs
of infection were observed in the ΔHSP70-II-infected
hamsters; instead the animals remained healthy. At this
point, 9 months post-infection, animals were sacrificed
and individually analyzed for the present of parasites in
liver and spleen by limiting dilution. No parasites were
found in any of the tissues, and the organs showed a nor-
mal morphology. In parallel, the capacity of spleen cells,
from infected and control hamsters, to proliferate in the
presence of parasite antigens was assessed (Table 1).
Remarkably, splenocytes from ΔHSP70-II-infected
hamsters specifically proliferated in response to Leishma-
nia antigens (2-3 fold above control cells). Furthermore,
splenocytes of ΔHSP70-II-infected hamsters showed a
proliferation capacity, similar to control animals, after sti-
mulating with the mitogen ConA (Table 1). It should be
noticed that infection of hamsters with virulent L. dono-
vani (and also with L. infantum; our unpublished data)
leads to a significant suppression of the ability of spleen
cells to respond to ConA [47]. In summary, these data
suggest that inoculation with the ΔHSP70-II mutant was
able to elicit a long-lasting immune response, without
affecting the normal function of the immune system.
Conclusions
A vaccine against leishmaniasis seems to be feasible
since most individuals that were once infected with
Leishmania become resistant to clinical infection when
later exposed to the parasite. However, despite great
research effort, leishmanization with live Leishmania
parasites remains the only vaccine with proven efficacy
against human leishmaniasis. Genetic modification of
Leishmania to reduce virulence, yet maintaining immu-
nogenicity, is of current interest in vaccine research.
According to the levels of IgG1 and IgG2a antibodies,
and the NO production, the immunization of mice with
the ΔHSP70-II deletion mutant appears to be eliciting
predominantly Th1 responses, independently of the
route of administration (intraperitoneal, intravenous or
subcutaneous). In addition, we found that immunization
of BALB/c with ΔHSP70-II promastigotes lead to an
effective immune response able to protect these mice
against infection with L. major.
In summary, present results offer hope for the develop-
ment of a live-attenuated vaccine against Leishmania
based on this mutant line. However, we are aware that
this work constitutes a preliminary study and that further
experiments, using more appropriate models for LV
(hamsters and/or dogs), are needed. An important con-
cern with live-attenuated vaccines is their safety, as there
are fears that the parasite may revert back to a virulent
form or cause lesions in immunesuppressed individuals.
Interestingly, the low numbers of parasites found after
infection with ΔHSP70-II promastigotes in hamsters,
BALB/c mice and even in SCID mice (lacking both T and
B cells) support the idea that this mutant would be a safe
vaccine, which might be helpful to design prevention
Table 1 Immunological responses elicited in golden hamsters infected with ΔHSP70-II parasites
Proliferation ± SD (cpm)a
IgG reactivitya Medium SLA ConA
Uninfected 0.12 ± 0.01 4444 ± 840 4467 ± 674 230427 ± 14932
ΔHSP70-II 0.25 ± 0.03 4646 ± 763 9515 ± 1953 264887 ± 12337
aSee Methods for experimental details
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strategies against Leishmania infection in both dogs and
humans [48]. Additionally, based on this safety, this
Δhsp70-II line could also have usefulness as a platform
for introduction of immunoprotective antigens relevant
to leishmaniasis or even to other diseases.
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